The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).
 
Matthias Holdhoff
Honoraria - Pfizer
Research Funding - Bristol Myers Squibb Foundation (Inst); Vanquish Oncology (Inst)
Other Relationship - Advarra; Parexel
 
Xiaobu Ye
No Relationships to Disclose
 
Roy E. Strowd
Consulting or Advisory Role - Alexion Pharmaceuticals; Monteris Medical; Monteris Medical; Novocure
Research Funding - Alpha Omega Alpha; American Board of Psychiatry and Neurology; Jazz Pharmaceuticals; NIH; Southeastern Brain Tumor Foundation
Patents, Royalties, Other Intellectual Property - Elsevier, book royalties; Lecturio, lecture royalties
Other Relationship - American Academy of Neurology (AAN)
 
Louis B. Nabors
Patents, Royalties, Other Intellectual Property - IP related to my lab research only
 
Tobias Walbert
Consulting or Advisory Role - Alexion Pharmaceuticals; AstraZeneca/MedImmune/Spirogen; Novocure; Orbus Therapeutics
Speakers' Bureau - AstraZeneca/MedImmune
 
Frank S. Lieberman
Research Funding - Black Diamond Therapeutics (Inst); Chimerix (Inst); Novocure (Inst)
 
Stephen Joseph Bagley
Consulting or Advisory Role - KIYATEC; Novocure; Sumitomo Dainippon Pharma Oncology
Research Funding - C2i genomics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Novocure (Inst); Tempus (Inst); Tmunity Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of intellectual property of the University of Pennsylvania licensed to Novartis: Combination Therapies of EGFRvIII Chimeric Antigen Receptors and PD-1 Inhibitors, US. Patent No. 62/809,245.
Travel, Accommodations, Expenses - Northwest Biotherapeutics
 
John B. Fiveash
Employment - Varian Medical Systems
Honoraria - Varian Medical Systems
Research Funding - Varian Medical Systems
Travel, Accommodations, Expenses - Varian Medical Systems
 
Joy D. Fisher
No Relationships to Disclose
 
Serena Desideri
No Relationships to Disclose
 
Marc Engelhardt
Employment - Basilea Pharmaceutical
Leadership - Basilea Pharmaceutical
Stock and Other Ownership Interests - Basilea Pharmaceutical
Patents, Royalties, Other Intellectual Property - Basilea Pharmaceutical
 
Thomas Kaindl
Employment - Basilea Pharmaceutical
Stock and Other Ownership Interests - Basilea Pharmaceutical
 
Heidi A Lane
Employment - Basilea Pharmaceutical
Stock and Other Ownership Interests - Basilea Pharmaceutical
Patents, Royalties, Other Intellectual Property - Basilea Pharmaceutical
 
Stuart A. Grossman
Stock and Other Ownership Interests - Axxia Pharmaceuticals
Consulting or Advisory Role - Abbvie; Medicenna; Midatech Pharma
Patents, Royalties, Other Intellectual Property - Patent related to a subcutaneous polymeric opioid delivery system have been awarded.
Other Relationship - Myosin; Travecta Therapeutics
 
Lawrence Kleinberg
Consulting or Advisory Role - Novocure
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Incyte; Novartis (Inst)